Viewing related articles

Using a matrix approach to address challenges for potency assay development for in vivo and ex vivo gene therapies.

The gene therapy field is advancing rapidly and though there has been significant progress, there are yet relatively few commercial products approved globally reflecting the infancy of this modality. Some therapies have suffered setbacks due to adverse side effects in patients and limited knowledge about product quality.   With more than 400 gene therapies currently under development, it is more important than ever to improve our...

read more

Challenges for potency assay development for in vivo and ex vivo gene therapies and the matrix approach

This paper highlights some of the challenges to develop potency assays for gene therapies and promotes a potential solution. It seeks to establish Industry alignment on the benefits of a matrix approach and provides high level guidance on how to adopt this strategy towards potency assay development and validation with examples for in vivo and ex vivo GT processes.

read more

Host cell protein (HCP): Risk assessment tool and papers

Host cell protein (HCP) constitutes a significant class of process-related impurities in biological drugs. The complexity and diversity of residual HCP composition in biologics and the incomplete understanding of their potential impact also pose unknown risks besides some of the well-known risks from certain problematic HCPs. This can make the HCP risk assessment and management an industry-wide challenge.

Although attempts have been made to address these challenges in the biopharmaceutical industry, gaps still remain in terms of how to manage the risks associated with HCP during bioprocess development. To this end, a BioPhorum Development Group (BPDG) HCP working team consisting of several companies initiated a collaboration among its members to align industry best practices and generated a generic risk assessment tool to manage HCP-related risks identified during biologics development from both an assay development and process development perspective.

Distinct from individual HCP identity-based safety risk assessment, this tool focuses on the manufacturing process through process development. The tool will help companies to tackle the risks associated with HCP within the development lifecycle. The intent the tool is to provide a template in order to guide process development teams using a scientific knowledge-based risk control strategy, where process or assay changes may be deemed necessary to reduce the risks caused by inadequate removal of HCP upon experimental studies to assess impact of HCPs on product safety, efficacy, and stability.

Companies implementing this risk management model can apply their own unique set of circumstances, products and experience to perform a more comprehensive and robust assessment of risk, identify the priority in which risk reduction steps should be applied.

read more

Host cell protein (HCP): A multi-company collaboration: Views on “high risk” HCP: Presentation

This presentation compliments the papers and risk manage tool. The goal of the Host Cell Protein (HCP) Workstream is to deliver for industry alignment; building a common understanding of agency requirements for HCPs through benchmarking and gap analysis of guidance. To widen understanding of the risks associated with HCPs and what can be done to mitigate these risks during process development. This poster available to ‘Members Only’ discusses, Industry benchmarking, understanding of what companies are doing in order to understand HCP risk through the stages of development, risk assessment methodology and risk scoring tool to perform qualitative and semi-quantitative assessment of risk when dealing with HCPs, case studies and next steps.

read more